Peritoneal Mesothelioma Treatment Options in 2026

If you or someone you love has been diagnosed with peritoneal mesothelioma and you're trying to understand what treatment actually looks like in 2026, this page is the place to start.

Peritoneal mesothelioma is a serious diagnosis, but it isn't the uniformly fatal disease it was twenty years ago. The arrival of CRS-HIPEC, the combined surgery and heated chemotherapy described throughout this page, has changed what's possible for the patients who qualify: in a 2024 multi-center study, median survival after CRS-HIPEC was about 44 months, and some patients live well beyond that.¹ Treatment for patients who aren't surgical candidates has improved too, and immunotherapy and clinical trials have widened the options further. What hasn't changed is that outcomes depend heavily on where the treatment is done.

This page walks through each treatment in the depth you'd want before a serious conversation with an oncology team: what CRS-HIPEC involves and who's a candidate, which chemotherapy regimens are used and when, where immunotherapy fits, what radiation and clinical trials offer, and what each of these costs. For the disease itself, including symptoms, diagnosis, staging, cell types, and prognosis, see the main peritoneal mesothelioma page.

The treatment landscape today

Peritoneal mesothelioma is treated with combinations of approaches rather than a single drug or operation, and it has one feature that sets it apart from most cancers: for patients who qualify, the primary treatment isn't surgery or chemotherapy alone but a single combined procedure, CRS-HIPEC, that delivers both in one operating session. What varies from patient to patient is whether that procedure is an option, what's combined with it, and in what order.

What drives the treatment plan

Three things determine more about a patient's options than anything else. The first is how far the disease has spread across the abdomen, captured by the PCI score: lower scores generally mean surgery is feasible and outcomes are better, while a high score usually points toward systemic treatment instead. The second is the cell type: epithelioid disease, especially the tubulopapillary pattern, responds best to surgery, while sarcomatoid disease generally isn't treated surgically and biphasic disease falls in between. The third is overall fitness, since CRS-HIPEC is a demanding operation that takes the reserve to tolerate a long surgery and an extended recovery. The full detail on how spread is scored and how the cell types behave is on the main peritoneal mesothelioma page; here, the point is that these three together decide which of the treatments below apply.

How the treatments fit together

For patients who qualify, treatment is built around CRS-HIPEC. Chemotherapy may be given before the operation to shrink disease and gauge how it responds, delivered into the abdomen during the operation as the HIPEC component, or given afterward when some disease remains. For patients who aren't surgical candidates, systemic chemotherapy becomes the primary treatment rather than a step toward surgery, and immunotherapy and clinical trials enter the picture for specific situations. The intent of treatment shifts with the situation too: for a fit patient with favorable, low-burden disease, the goal of aggressive treatment is long-term disease control measured in years; for someone with advanced or aggressive disease, the goal is more often controlling the disease and protecting quality of life. Both are legitimate goals, and being clear about which one applies makes the rest of the conversation easier.

Where you're treated is the biggest variable

The single most important point about treating this disease is that where it happens matters more than in almost any other cancer. CRS-HIPEC takes a specialized surgical team, dedicated perfusion equipment, surgical-ICU capacity, and a tumor board that reviews peritoneal disease routinely rather than occasionally. The difference shows up in a national database study of 2,682 patients: academic facilities performed cancer-directed surgery about twice as often as community facilities (42.9 versus 20.2 percent) and gave chemotherapy on the day of surgery, the database's marker for HIPEC, nearly three times as often (28.8 versus 10.4 percent). Unadjusted five-year survival was 29.7 percent versus 18.3 percent, and community treatment remained associated with a higher risk of death after adjustment for measured differences.²

That's why a consultation at a high-volume peritoneal mesothelioma center is worth pursuing even when most day-to-day care will be delivered closer to home. At a major center, the plan is built by a multidisciplinary tumor board, with surgeons, oncologists, radiologists, and pathologists who see this disease regularly weighing in together before a recommendation is made. At a practice that sees a case every few years, that kind of coordinated review usually isn't available, and the plan that results can look very different.

CRS-HIPEC: cytoreductive surgery with heated chemotherapy

CRS-HIPEC is the treatment that changed peritoneal mesothelioma from a disease measured in months to one where many patients live years. Understanding what it involves, who qualifies, and what it can and can't do is the most important clinical knowledge a newly diagnosed patient can have.

What CRS-HIPEC involves

The procedure has two parts, done in sequence during a single operation.

Cytoreductive surgery is the first part. The goal is to remove every visible tumor deposit from the peritoneal surfaces, which is different from a typical cancer operation that removes one discrete mass. Because the disease spreads in sheets and nodules across the abdomen, the surgeon works systematically through every region where tumor is present, which can mean removing the omentum (the fatty apron over the organs), stripping peritoneum from the abdominal wall, diaphragm, and pelvis, and sometimes removing parts of involved organs such as the spleen or sections of bowel. The aim in every case is to leave no visible disease (a CC-0 result) or only deposits smaller than 2.5 mm (CC-1), the size the heated chemotherapy that follows is thought to reach.

Hyperthermic intraperitoneal chemotherapy is the second part, given immediately, while the patient is still on the operating table. The abdominal cavity is bathed in a heated chemotherapy solution (typically cisplatin, mitomycin-C, or a platinum-based combination) and circulated through the abdomen, commonly for 60 to 90 minutes at about 41 to 43°C, with the exact protocol varying by center. The heat does two things: it helps the drug penetrate tumor tissue more deeply, and it's directly toxic to cancer cells at temperatures healthy tissue can tolerate. Delivering the drug right into the abdomen also allows far higher concentrations than could ever be given through an IV without poisoning the rest of the body, which is why HIPEC can reach microscopic disease that systemic chemotherapy can't.³

The full operation often runs six hours or more and may be followed by time in the ICU; hospital stays commonly run one to two weeks and are longer when complications arise.

What the survival data shows

The change CRS-HIPEC produced in this disease is one of the more striking stories in surgical oncology, built up over decades at a small number of centers that committed to it early. In a 2024 multi-center study, the 54 patients who underwent CRS-HIPEC had a median overall survival of 44.6 months, compared with 11.2 months for patients with metastatic disease and 12.6 months for patients who were medically inoperable or could not have a complete cytoreduction; one-year survival was 93 percent after a complete (CC-0 or CC-1) cytoreduction.¹ In a U.S. national database of 1,514 patients with nonmetastatic disease, median survival was 61 months after CRS-HIPEC, 52 months after surgery with other chemotherapy, and 17 months with chemotherapy alone; the authors note these observational data do not prove that the treatment caused the difference.⁴ Specialty-center series summarized in the PSOGI/EURACAN guideline have reported median survival ranging from about three to nearly eight years after cytoreduction, with the longest results in epithelioid disease that was completely removed.⁷ Among 149 patients reviewed by the UK and Ireland national multidisciplinary team, including patients who didn't have surgery, survival measured from that review was 62.6 percent at three years.⁶

Two honest caveats belong with those numbers. They come largely from patients selected as good surgical candidates and treated at experienced centers, so some of the difference reflects who gets the operation, not only the operation itself. And the evidence base is built on these institutional series and registries rather than randomized trials; no trial has randomized patients to surgery or no surgery, largely because the disease is rare, selection is highly individualized, and the observed differences are large. Even allowing for that, the gap between CRS-HIPEC and chemotherapy alone is large and consistent enough that the procedure is the established standard for patients who qualify.

Who qualifies

CRS-HIPEC isn't right for everyone, and careful patient selection is how its benefit is protected and its risks kept in check. The criteria that matter most:

• Tumor burden (PCI). Lower scores carry better odds of a complete cytoreduction and better outcomes. A high PCI alone doesn't rule surgery out; where the disease sits, especially how much the small bowel is involved, and whether complete cytoreduction looks achievable matter as much as the number.^1,7
• Cell type. Epithelioid disease, especially the tubulopapillary pattern, is the most favorable. Biphasic disease is evaluated case by case, and sarcomatoid disease generally isn't treated surgically.⁵
• Overall fitness. A long operation, an ICU stay, and an extended recovery require adequate cardiopulmonary reserve. Patients who are fully active or nearly so (an ECOG performance status of 0 or 1) are generally candidates; significant frailty or major other illness often isn't compatible with the procedure.⁷
• Disease confined to the abdomen. CRS-HIPEC treats disease within the peritoneal cavity. Significant spread beyond it, to the lungs, liver, bone, or distant lymph nodes, generally shifts the plan to systemic treatment, so preoperative staging is meant to rule that out.

What CRS-HIPEC can and can't do

Even in the best candidates, CRS-HIPEC is cytoreductive rather than reliably curative. The goal is to remove as much disease as possible and use the heated chemotherapy to reach what's left, which can produce long disease-free intervals and, in favorable cases, survival measured in many years. But it isn't a guarantee against recurrence, and it's the foundation of a coordinated plan, often combined with chemotherapy before or after, rather than a standalone fix. The patients who benefit most are those for whom it's part of a planned sequence of care at a center that performs it often. If you've been told you might be a candidate, the most valuable next step is an evaluation by a surgeon who does this operation regularly, because the outcomes vary enormously with patient selection, staging rigor, and surgical experience.

Chemotherapy

Chemotherapy plays a more varied role in peritoneal mesothelioma than in most cancers, because its relationship to surgery isn't a simple before-or-after. Depending on where a patient is in their care, chemotherapy may be given to shrink disease ahead of surgery, delivered into the abdomen during the operation itself, used afterward to mop up what remains, or given as the main treatment when surgery isn't an option. Knowing which role it's playing is the context for the specific drugs an oncologist may recommend.

The roles chemotherapy plays

Chemotherapy is used in four distinct ways in this disease.

• Before surgery (neoadjuvant). For a patient whose tumor burden sits in the borderline range, a few cycles of systemic chemotherapy first can shrink the disease and show how it responds. If it responds and the burden falls into a more favorable range, the patient proceeds to CRS-HIPEC; if it progresses, that itself is useful information, flagging an aggressive disease where surgery is less likely to help. This is a selective, center-dependent strategy rather than a proven way to convert unresectable disease: systemic chemotherapy often doesn't shrink peritoneal disease enough to make it removable, and retrospective results have been mixed.⁷
• During surgery (the HIPEC component). The heated chemotherapy delivered into the abdomen during CRS-HIPEC, described in the section above, is itself one of chemotherapy's roles: high-concentration drug delivered locally to reach microscopic disease at the highest-risk sites.
• After surgery (adjuvant). Systemic chemotherapy may be given after CRS-HIPEC, particularly when cytoreduction was incomplete or the disease showed aggressive features. The evidence for chemotherapy after surgery is mixed, the PSOGI/EURACAN guideline suggests follow-up alone may be reasonable for patients with favorable features, but recommends chemotherapy after surgery for patients with at least one adverse feature, such as incomplete cytoreduction, non-epithelioid histology, involved lymph nodes, a high Ki-67, or a high PCI. Practice varies by center.^7,8
• As the primary treatment. For patients who aren't surgical candidates, systemic chemotherapy is the main treatment rather than a step toward surgery, with the goal of controlling the disease and easing symptoms.

The standard regimen: pemetrexed and cisplatin

The combination of pemetrexed (originally branded Alimta) and cisplatin is the first-line systemic regimen in peritoneal mesothelioma, as it is in pleural disease. One honest point of context: there's never been a landmark Phase III trial of this combination specifically in peritoneal patients, so its use is extrapolated from the strong pleural evidence and consistent experience across peritoneal centers, rather than proven in a dedicated peritoneal trial.⁹

The two drugs work through complementary mechanisms. Pemetrexed is an antifolate, blocking the folate-dependent enzymes cancer cells need to build DNA and RNA; it requires vitamin B12 and folic acid supplementation started before treatment and continued throughout, which reduces toxicity to healthy cells without blunting the effect on the tumor. Cisplatin is a platinum drug that damages DNA directly, in ways cancer cells can't repair. Hitting cell replication and DNA integrity at once works better than either drug alone. Treatment usually runs six cycles, given every three weeks, with imaging between cycles to judge response.

In the 2024 multi-center study, patients treated without surgery had a median survival of about 11 to 13 months, and median progression-free survival on first-line treatment was 5 months for non-metastatic patients and 2.2 months for metastatic patients. Earlier studies of pemetrexed-based chemotherapy in peritoneal disease reported disease control (shrinkage or stability) in about 70 percent of patients and measurable shrinkage in about a quarter.¹ That's meaningful against untreated disease, but far short of what CRS-HIPEC achieves in candidates, which is why surgical-candidacy assessment matters so much. When chemotherapy is used instead to set up a successful CRS-HIPEC, its real contribution is measured by the surgery it enables, not by these standalone numbers.

When cisplatin isn't an option: carboplatin

Not every patient can take cisplatin. Impaired kidney function, pre-existing nerve damage, significant hearing loss, or other conditions can make it too toxic. In those cases carboplatin replaces it as the platinum partner for pemetrexed. Carboplatin is easier on the kidneys and nerves, though it suppresses the bone marrow more. It hasn't been tested in a dedicated peritoneal trial, but it's widely used and endorsed in guidelines as an appropriate alternative for patients who can't safely take cisplatin, and given the age and other health conditions common in this disease, it's often the more practical choice.⁹

The alternative regimen: gemcitabine and cisplatin

For patients who can't take pemetrexed, gemcitabine combined with cisplatin (or carboplatin) is the established alternative. Gemcitabine is a nucleoside analogue, a molecule that mimics a building block of DNA and jams the replication process when cancer cells try to use it; paired with cisplatin's DNA damage, the two produce complementary effects. In mesothelioma, gemcitabine-cisplatin has shown response rates from 12 to 48 percent and median survival from 9.4 to 14.7 months in published mesothelioma series, and the PSOGI/EURACAN guideline lists cisplatin-gemcitabine as a second-choice regimen for patients who can't take pemetrexed.^7,9

Immunotherapy

Immunotherapy has reshaped mesothelioma treatment over the past several years, but its place in peritoneal disease specifically is narrower and less settled than in the pleural form, and it's worth being clear about why.

How checkpoint immunotherapy works

Mesothelioma tumors, like many cancers, exploit the immune system's own off switches to avoid attack. They display proteins, most notably PD-L1, that bind receptors on immune T-cells and effectively tell them to stand down. Checkpoint inhibitors block those off switches. The two combined in mesothelioma are nivolumab, which blocks the PD-1 receptor and restores the immune system's ability to see the tumor, and ipilimumab, which blocks a separate checkpoint called CTLA-4 and raises the overall level of T-cell activity. The two drugs act on complementary checkpoints.¹²

What the evidence shows, and where it comes from

The strongest evidence for immunotherapy in mesothelioma comes from a trial in pleural, not peritoneal, disease. The CheckMate 743 trial established nivolumab plus ipilimumab as a first-line option for unresectable pleural mesothelioma, with median survival of 18.1 months versus 14.1 for chemotherapy, and the benefit was most dramatic in patients with non-epithelioid (sarcomatoid and biphasic) disease, where it roughly doubled survival.¹⁰ Longer follow-up showed the advantage held up over years, with more immunotherapy patients alive at three years than with chemotherapy.¹¹

There's no equivalent randomized trial in peritoneal mesothelioma, so its use here is extrapolated from that pleural evidence and from smaller peritoneal experience. That's an honest limitation, not a reason to dismiss the approach: the biology is shared, and for the peritoneal patients most likely to benefit, the case for trying it is reasonable. It does mean immunotherapy in peritoneal disease is best approached through a specialist, and often within a clinical trial.

Where immunotherapy fits in peritoneal disease

For the typical patient with epithelioid disease who's a good CRS-HIPEC candidate, immunotherapy isn't a standard first-line treatment; surgery and chemotherapy come first. Its clearest roles in peritoneal disease are three. The first is non-epithelioid disease (sarcomatoid, or biphasic with a significant sarcomatoid component), where nivolumab plus ipilimumab roughly doubled survival compared with chemotherapy in the pleural trial (18.1 versus 8.8 months), PD-L1 levels did not reliably predict benefit, and surgery usually isn't an option anyway.¹⁰ The second is disease that has come back after CRS-HIPEC. The third is disease that has progressed on chemotherapy. In those settings, immunotherapy can produce durable responses in some patients. Whether it fits a particular situation depends on the cell type, prior treatment, overall health, and what trials are available, which is a conversation for a mesothelioma specialist.

Radiation, emerging therapies, and clinical trials

Surgery, chemotherapy, and immunotherapy make up the core of standard care. Radiation plays only a small role in peritoneal disease, and a pipeline of investigational approaches is in development, some building on the CRS-HIPEC foundation, others targeting molecular weaknesses in the tumor or new ways of activating the immune system. Several immunotherapy combinations beyond nivolumab-ipilimumab (such as durvalumab with chemotherapy, or dual-checkpoint combinations) are also under study in mesothelioma. For many of these, a clinical trial is the only way to access them today.

Radiation therapy

Radiation has almost no role in treating peritoneal mesothelioma, for a straightforward anatomical reason: the peritoneum lines the entire abdominal cavity and drapes over the bowel, liver, stomach, kidneys, and other organs that can't tolerate the doses needed to kill diffuse tumor. Delivering a tumor-killing dose across that whole volume without seriously injuring those organs isn't possible with current technology. The one exception is palliative radiation aimed at a single symptomatic spot, such as a painful mass pressing on a nerve, to relieve that specific symptom rather than treat the disease. If radiation is proposed for peritoneal mesothelioma in any broader role, a second opinion at a major center is warranted.

Intraperitoneal maintenance chemotherapy

One investigational area is specific to peritoneal disease: continuing chemotherapy delivered directly into the abdomen after CRS-HIPEC, to extend the local-delivery advantage of HIPEC past the operation itself. Two versions are being studied. Early postoperative intraperitoneal chemotherapy (EPIC) delivers drug into the abdomen in the days right after surgery, before scar tissue forms and while microscopic disease is still most reachable. Delayed maintenance delivers periodic intraperitoneal drug over the following weeks to months, aiming to suppress recurrence before it becomes visible. Neither is universal practice, and the evidence is still developing. The PSOGI/EURACAN guideline says these regimens could be proposed alongside systemic chemotherapy after CRS-HIPEC when the patient's recovery allows, so some centers offer them outside trials as well as within them.^3,7

Targeted and molecular approaches

Peritoneal mesothelioma doesn't usually carry the simple driver mutations that make targeted therapy straightforward in some other cancers, but molecular profiling of the tumor sometimes turns up alterations worth acting on, especially when considering clinical trials. Testing for inherited (germline) variants such as BAP1 is a separate question that is increasingly recommended for patients with mesothelioma. A few are most relevant. BAP1 loss, common in epithelioid peritoneal disease, doesn't yet have a drug aimed directly at it, but its effects on DNA repair are being explored as a vulnerability, including with PARP inhibitors and EZH2 inhibitors, so far only in research. CDKN2A deletion, more common in sarcomatoid and biphasic disease, is being studied as a target for CDK4/6 inhibitors. And a small minority of patients carry rare gene fusions: NTRK fusions have drugs approved for solid tumors of any type, while ALK and ROS1 inhibitors are approved for lung cancer and would usually require off-label use or a basket trial in mesothelioma. The odds of finding an actionable alteration aren't high, but the cost of not looking is a missed option that can't be recovered later, so it's worth asking whether tumor profiling has been done.

Mesothelin-directed therapies

Mesothelin is a protein found on the surface of most peritoneal mesothelioma cells but largely absent from healthy tissue, which makes it an appealing target for treatments that concentrate their effect on the tumor. Several have been studied: antibody-drug conjugates such as anetumab ravtansine (whose randomized trial in pleural mesothelioma did not meet its main goal), which carry a cell-killing payload directly to mesothelin-bearing cells; an older mesothelin-targeting immunotoxin (SS1P); and mesothelin-directed CAR T-cell therapy, which engineers a patient's own immune cells to attack mesothelin-expressing tumor. CAR T-cell therapy for solid tumors like this is genuinely at the research frontier, with early signals of activity but meaningful availability outside trials still years away rather than months. Because mesothelin is especially highly expressed in epithelioid peritoneal disease, this is one of the more peritoneal-relevant areas of research, and if these approaches reach clinical use, peritoneal patients may be among those who benefit most.

Accessing clinical trials

Clinical trials are one of the most underused options in this disease, and at major centers they're a routine part of the treatment conversation rather than a last resort. The National Library of Medicine maintains ClinicalTrials.gov, a searchable database of studies, and the National Cancer Institute keeps its own trial-search resources, but the eligibility criteria are hard to interpret without help, and most community oncologists don't routinely search them. The more effective path for most patients is to consult a peritoneal mesothelioma specialist at a high-volume center, where the open trials, eligibility, and practical details are part of the standard assessment. A few things are worth knowing: most plans must cover routine care costs in qualifying trials, while the trial usually covers the experimental drug and research-only testing, though coverage varies by plan and is less certain out of network, so confirm it with the study team and insurer; travel and lodging for a distant trial can sometimes be covered by assistance programs or, for asbestos patients, by a legal recovery; and joining a trial doesn't rule out standard treatment afterward if the trial therapy doesn't work.

What peritoneal mesothelioma treatment costs

Peritoneal mesothelioma treatment is among the most expensive care in modern medicine, but the word "cost" hides several different numbers that aren't interchangeable, and confusing them is the most common mistake families and websites make. A hospital's billed charge is rarely what anyone actually pays. An insurer's negotiated rate is lower. A Medicare payment limit is set by formula. And the patient's own out-of-pocket share is different again, shaped by the specific plan, the network, and how long treatment runs. Two more distinctions matter just as much: the cost of the drugs is not the same as the cost of the care around them, and a planning estimate is not a guarantee. The figures below are planning ranges, and they vary with insurance, region, center, complications, and how long treatment continues.

What CRS-HIPEC costs

For surgical candidates, CRS-HIPEC is the single largest cost, driven by a long operation, often an ICU stay, and a hospitalization that commonly runs one to two weeks. A 2024 analysis of 100 CRS-HIPEC operations at a U.S. academic center (most for colorectal or appendiceal cancer; 15 percent for mesothelioma or other tumors) found:¹⁵

Measure	Median (middle half of cases)
Hospital's direct cost of the operation and stay	$44,770 ($35,933–$60,207)
Total amount the hospital and surgeons collected	$52,263 ($38,355–$85,605)
Length of stay	10 days (7–15)

Those are the hospital's costs and the payments it received, not the billed charges on an itemized bill, which are usually much higher. Several things drive the range. The length of the hospital stay had the biggest effect on cost, and major complications, which occurred in 28 percent of operations, had the biggest effect on length of stay. Complexity matters too: a cytoreduction that requires bowel resection, diaphragm stripping, and removal of the spleen takes more operating time than disease confined to the omentum. Costs vary by region and institution, and an Italian center reported a lower median cost under its national health system.^13,15

What the drugs and chemotherapy cost

Here a common misconception is worth clearing up. The chemotherapy drugs themselves are now inexpensive. Pemetrexed lost its patent and is available as a generic, so the high five-figure "chemotherapy drug cost" figures still circulating online reflect old branded pricing, not what the drugs cost today. Priced from 2026 Medicare payment limits for generic pemetrexed, the drug-only cost of a standard six-cycle pemetrexed-cisplatin course is typically well under a few thousand dollars, though some branded pemetrexed products billed under different codes cost far more.

What costs real money is the care around the drugs, not the drugs themselves: the infusion visits, hydration, anti-nausea medication, lab monitoring, imaging, and management of any complications. A review of mesothelioma care costs found the average mesothelioma hospitalization alone cost over $24,000 in 2014.¹⁴ So a course of systemic chemotherapy can be genuinely expensive, but the expense sits in the delivery of care, not in the price of the generic drugs in the bag.

What immunotherapy costs

When immunotherapy is used, the relationship flips: there, the drug itself is the dominant cost, and a course of checkpoint immunotherapy can run well into six figures at list prices. Coverage is also less predictable than for chemotherapy, for the reason noted earlier on this page: the checkpoint drugs are FDA-approved for pleural mesothelioma, on the strength of the pleural trials, but not for the peritoneal form, which has no approval of its own. Using them for peritoneal disease is therefore off-label, meaning an approved drug prescribed for an indication it isn't formally labeled for, and some insurers contest off-label use because there's no approved label or large trial behind it for that exact situation. Coverage and appeals depend on the plan and the case; where a legal recovery is obtained, it may help with documented costs that coverage doesn't meet. Immunotherapy is a smaller part of the cost picture for the typical peritoneal patient than for pleural patients, since it isn't standard first-line treatment here, but for the non-epithelioid and recurrent cases where it's used, it's a significant number.

How families pay for this

Added together, the surgery, the hospitalization, the chemotherapy, any immunotherapy, and the travel, lodging, and lost income around them can push the full cost of treating peritoneal mesothelioma well into six figures, and insurance rarely covers all of it. For patients with a valid asbestos claim, the documented cost of treatment can be part of what a claim seeks to recover, and for many of our clients the legal case was, in practical terms, about funding access to this specific care. The channels (trusts, lawsuits, VA benefits, and disability programs) and how they fit together are covered on the main peritoneal mesothelioma page; how quickly compensation moves and what it can cover depends on the situation, and deadlines vary by state, so it's worth asking early.

How one family paid for this care

This continues the composite example from our main peritoneal mesothelioma page, narrowed here to the treatment journey. It's illustrative, not a real client.

Marcus is the 52-year-old with epithelioid peritoneal mesothelioma we followed on that page. Here the question is narrower: how his family actually paid for the care described above.

His local oncologist, honest that he'd treated only a couple of cases like this, laid out chemotherapy close to home. The plan a high-volume peritoneal program eventually built was the better one: CRS-HIPEC, the combined surgery and heated chemotherapy that offers the best odds in this disease, done by a team that performs it often. But the obstacles were practical, not medical. The center was a long drive away, so the workup and the operation meant repeated travel and lodging. Parts of the care his team recommended were ones his insurer fought. And a long operation followed by weeks of recovery meant months when Marcus couldn't work.

None of those are medical problems, and all of them are the kind a legal recovery is built to solve. While treatment moved forward, Marcus's claims moved alongside it. Where the written agreement and applicable law permitted it, the firm advanced the travel and lodging up front, so getting to the right surgical team didn't wait on a settlement. When insurance fought parts of the care, covering the gap became part of what the recovery was for. The income that stopped when Marcus couldn't work was replaced, and his wife Steph could take time off to be with him through the surgery and the early recovery without the mortgage and the kids' lives coming apart at the same time.

Recoveries aren't always that large or that quick; trust payments are often a fraction of a claim's scheduled value, and lawsuits take longer. The point isn't the specific dollars, it's the sequence. The medical decisions got made on medical grounds, because the cost question was being handled on a separate track. For most families we work with, that's the whole value of calling early: it lets the surgical team decide the medicine, instead of the insurance company deciding it by default.

This example is general. Every case depends on the diagnosis, the treatment plan, the family situation, the available evidence, and applicable law.

Getting to a specialty center

The catch with CRS-HIPEC is that it's done well at only a limited number of high-volume centers, concentrated in a relatively small number of cities, so getting to one usually takes some planning. The good news is that it's more doable than most people expect, and you don't have to sort it out alone.

A few things make the process smoother:

• Gather your records first. A center will want the pathology report with the immunohistochemistry results and, if available, the specific cell type and any nuclear grade; all imaging with the actual images, not just the written reports; any operative reports from prior surgery; and a short summary of treatments so far. Having these ready speeds up the assessment.
• You usually don't need a referral. Most major peritoneal programs have an intake coordinator and will take contact directly, from you or from us, so you don't have to wait on a local oncologist to refer you, which sometimes doesn't happen quickly.
• Ask about a telehealth consultation. Many centers now do the initial review of records and imaging by video, so a specialist can give an early read on surgical candidacy and options before you travel anywhere.
• Expect a possible diagnostic laparoscopy. For borderline cases, a center may want to look inside the abdomen directly to assess the extent of disease before committing to a major operation, often as a separate step ahead of any surgical plan.

Where a case qualifies, we help with the logistics that put a distant center within reach: advancing the cost of travel and lodging when the written agreement and applicable law permit it, to be recovered as part of the claim, helping expedite appointments and transfer records, and pointing families to the nonprofit medical-travel and lodging programs that exist for cancer patients. The aim is simple, to make sure the right center is a real option rather than one ruled out by distance or cost.

Survivorship and recurrence

For patients who do well after CRS-HIPEC, the period that follows can look more normal than a peritoneal mesothelioma diagnosis first suggests: back to work, traveling, present for family milestones, with some patients living five, ten, or more years after a complete cytoreduction.⁷ But survivorship isn't only the absence of cancer. It involves ongoing monitoring and, for a meaningful share of patients, eventually managing a recurrence. Knowing what that looks like is part of understanding the treatment.

Surveillance after CRS-HIPEC

After surgery, patients are followed on a schedule of clinic visits and imaging (usually CT scans, sometimes with tumor-marker blood tests) at intervals that are closer together early on and spread out over time if things stay stable. The point of surveillance is to catch any recurrence while it's small and still treatable, and to manage the late effects of major abdominal surgery, including the scar-tissue adhesions that can occasionally cause a bowel obstruction and warrant prompt attention if symptoms suggest it. Surveillance is best handled by, or in coordination with, the center that performed the surgery, since they know what was done and what to watch for.⁷

If the disease comes back

Recurrence is common in peritoneal mesothelioma, even after a complete cytoreduction, and it isn't the end of the options. In selected patients, particularly those who did well the first time and whose recurrence is again confined to the abdomen, a repeat CRS-HIPEC is possible and is performed at experienced centers. For others, systemic chemotherapy, immunotherapy, or a clinical trial becomes the next step. As with the first round, the decisions are nuanced and best made at a high-volume center, and the same principle holds: where the recurrence is managed shapes what's possible.⁸

References

1. Yaşar S, Yılmaz F, Utkan G, et al. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024;31(9):6228–6236. doi:10.1245/s10434-024-15506-3
2. Welten VM, Fields AC, Malizia RA, et al. Survival outcomes for malignant peritoneal mesothelioma at academic versus community hospitals. J Gastrointest Surg. 2022;26(1):161–170. doi:10.1007/s11605-021-05084-0
3. Ray MD, Dhall K. Hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal surface malignancies: an evidence-based review. Curr Probl Cancer. 2021;45(6):100737. doi:10.1016/j.currproblcancer.2021.100737
4. Verma V, Sleightholm RL, Rusthoven CG, et al. Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol. 2018;25(7):2018–2026. doi:10.1245/s10434-018-6499-1
5. Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46(7):604–609. doi:10.1097/PAT.0000000000000181
6. Brandl A, Westbrook S, Nunn S, et al. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open. 2020;4(2):260–267. doi:10.1002/bjs5.50256
7. Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59. doi:10.1016/j.ejso.2020.02.011
8. Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–935. doi:10.1200/JOP.2016.011908
9. Borrelli EP, McGladrigan CG. A review of pharmacologic management in the treatment of mesothelioma. Curr Treat Options Oncol. 2021;22(2):14. doi:10.1007/s11864-020-00807-y
10. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. doi:10.1016/S0140-6736(20)32714-8
11. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–499. doi:10.1016/j.annonc.2022.01.074
12. Dumoulin DW, Aerts JG, Cornelissen R. Is immunotherapy a viable option in treating mesothelioma? Future Oncol. 2017;13(20):1747–1750. doi:10.2217/fon-2017-0234
13. Bagnoli PF, Cananzi FC, Brocchi A, et al. Peritonectomy and hyperthermic intraperitoneal chemotherapy: cost analysis and sustainability. Eur J Surg Oncol. 2015;41(3):386–391. doi:10.1016/j.ejso.2014.12.004
14. Borrelli E, Babcock Z, Kogut S. Costs of medical care for mesothelioma. Rare Tumors. 2019;11:2036361319863498. doi:10.1177/2036361319863498
15. Abreu AA, Farah E, Nix R, et al. Cost analysis and financial implications of a peritoneal surface malignancy program in the USA. Ann Surg Oncol. 2024;31:630–644. doi:10.1245/s10434-023-14442-y